Life Sciences and Healthcare

Advised the shareholders of UK Biocentre Limited on its sale to Azenta UK Ltd, a wholly owned subsidiary of Azenta Inc.

Advised MVM Partners, a leading life-science PE firm, on its EUR 32 million Series A investment in Avanzanite Bioscience.

Osborne Clarke advised neuroClues® on €10 million Series A fundraising to help their development of AI-powered neurological biomarkers from eye movements. 

Advised Amgen in two separate sets of UK proceedings relating to PAVBLU®, a biosimilar of aflibercept (EYLEA®), a recombinant human VEGF receptor fusion protein.  The first proceedings concerned patents relating to methods of treatment for certain...

Advised a consortium of London based life sciences research institutions on the formation of a joint venture to establish PharosAI, which promises to transform cancer care by unlocking NHS cancer data and hosting it on one powerful, secure, AI-ready...

Advised Epitopea, a transatlantic cancer immunotherapeutic company developing accessible off-the-shelf RNA-based immunotherapies, on its US$31 million pre-Series A financing out of Cambridge, UK and Montreal, Canada. 

Osborne Clarke has advised naturalX Health Ventures on its investment in Function Health as part of its oversubscribed Series B financing round.

Advised Epitopea, a transatlantic cancer immunotherapeutics company and global leader in exploiting a new class of untapped tumour-specific antigens (TSAs), on their $13.6M (£10.3M) seed investment from a transatlantic syndicate of top-tier life...

Acting for Halozyme Inc in revocation proceedings issued by Merck Sharp & Dohme (UK) Ltd.

Advised Hims & Hers Health, Inc on the UK, German and Dutch aspects of its acquisition of Eucalyptus

Advised CoaguSense on acquisition of DOASENSE DOAC testing business

Advised Schwabe Group on strategic investment in Synaptikon.

Osborne Clarke has advised the healthcare‑focused investor Gilde Healthcare on the acquisition of a majority stake in the Physio CKI Group from Kapital 1852. Read more.

Osborne Clarke advised SwissHealth Ventures, the venture capital arm of Swiss health insurer CSS, and Belgian investor Capricorn Partners on a EUR 11 million seed financing round of Frankfurt-based healthtech start-up Oska Health.

Advised Heqet Therapeutics, a King’s College biotech spin-out active in the field of regenerative medicine, on its £6.6m Series A financing round led by Claris Ventures and 2Invest.

Advised Uniphar plc, an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers, on its acquisition of UK-based brand commercialisation and...

Supported on the provision of Koa's flagship Foundations App to customers and the licensing in of content to the Foundations app, the preparation of documentation for Koa's strategically important collaboration with Dr Care Anywhere, the...

We advise Gama on bidding for high-value NHS framework agreements across the UK and play an integral role in helping the client to shape their bidding strategy.